Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

174
Delayed Quote. Delayed BATS Europe - 10/24 10:32:40 am
267.9 DKK   -0.59%
4d ago NOVO NORDISK A/S : Share repurchase programme
4d ago Novo Nordisk A/S - Share repurchase programme
4d ago NOVO NORDISK A/S : second best science employer in the world
 SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Copenhagen Stock Exchange
10/17/2014 10/20/2014 10/21/2014 10/22/2014 10/23/2014 Date
258.2 260.8 263.7 268.8 269.5 Last
3797267 3571113 3172111 3227713 1866252 Volume
+4.53% +1.01% +1.11% +1.93% +0.26% Change
Company
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes Care and Biopharmaceuticals segments.The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of... 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
Surperformance© rating of Novo Nordisk A/S
Trading Rating : Investor Rating :
More about the company
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO.B | DK0060534915 | 4-Traders
Full-screen chart
Financials ( DKK)
Sales 2014 88 384 M
EBIT 2014 33 679 M
Net income 2014 26 376 M
Finance 2014 7 236 M
Yield 2014 1,76%
Sales 2015 97 685 M
EBIT 2015 38 454 M
Net income 2015 29 626 M
Finance 2015 9 636 M
Yield 2015 2,02%
PER 2014 26,80
PER 2015 23,33
EV / Sales 2014 6,36x
EV / Sales 2015 5,73x
Capitalization 569 336 M
More Financials
Latest news on NOVO NORDISK A/S
2d ago NOVO NORDISK A/S : Data from Novo Nordisk Provide New Insights into Clinical Tri..
4d ago NOVO NORDISK A/S : Share repurchase programme
4d ago Novo Nordisk A/S - Share repurchase programme
4d ago NOVO NORDISK A/S : second best science employer in the world
10/17 NOVO NORDISK A/S : second best science employer in the world
10/16 NOVO NORDISK A/S : Jackie Scanlan joins Novo Nordisk as Corporate Vice President..
10/16 NOVO NORDISK A/S : Media Advisory - Dare to Tell the Truth About Vaginal Atrophy..
10/15 NOVO NORDISK A/S : Why Novo's Saxenda is not Victoza
10/15 NOVO NORDISK A/S : Takeda bulks up for Contrave launch
10/13 NOVO NORDISK A/S : Share repurchase programme
10/13 Novo Nordisk A/S - Share repurchase programme
10/08 NOVO NORDISK A/S : Data from Novo Nordisk Provide New Insights into Diabetes (Th..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF